Shopping Cart

Your shopping cart is currently empty

Edaravone

Name: Edaravone
Brand: TargetMol
SKU: T0407
Price: 29 USD
Availability: InStock
Rating: 5 (10 reviews)

Copy Product Info

🥰Excellent

Hot

Catalog No. T0407Cas No. 89-25-8

Alias MCI-186

Edaravone (MCI-186) is a potent new free radical scavenger used for the therapy of patients with acute brain infarction.

Edaravone

Copy Product Info

🥰Excellent

Hot

Purity: 99.98%

Catalog No. T0407Alias MCI-186Cas No. 89-25-8

Edaravone (MCI-186) is a potent new free radical scavenger used for the therapy of patients with acute brain infarction.

Pack Size	Price	USA Warehouse	Global Warehouse	Quantity
5 g	$29	In Stock	In Stock
1 mL x 10 mM (in DMSO)	$48	In Stock	In Stock

Add to Cart

Add to Quotation

In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]

All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.

Questions

Batch Information

Select Batch

Purity:99.98%

Appearance:Solid

Color:White to Yellow

Resource Download

COA HNMR LCMS

Product Introduction

Bioactivity

Description	Edaravone (MCI-186) is a potent new free radical scavenger used for the therapy of patients with acute brain infarction.
In vitro	Edaravone significantly improves neurological function in animals. Treatment with edaravone substantially reduces TUNEL-positive apoptotic cells and increases the expression of Bcl-2, while decreasing the immunoreactivity of Bax protein in the peri-infarct area. The research demonstrates that edaravone provides excellent protection against ischemic/reperfusion-induced brain injury through a Bcl-2/Bax protein-dependent anti-apoptotic mechanism. Following a 24-hour infusion of edaravone into murine brain tissue, there is a notable reduction in infarct volume and amelioration of neurological deficits. In the early stages post-reperfusion, edaravone significantly inhibits the accumulation of HNE-modified proteins and 8-OHdG in the penumbral region, reduces the expression of iNOS, diminishes microglial activation, and lowers the formation of nitrotyrosine. Edaravone also markedly attenuates renal function and pathological outcomes in rat kidneys, significantly reducing free radical production in renal tubular epithelial cells as indicated by fluorescence.
In vivo	Edaravone optimizes the state of NOS by reducing the detrimental isoforms iNOS and nNOS, while increasing the beneficial eNOS, thus favoring neuroprotection in ischemic stroke. It inhibits oxidation and enhances eNOS expression without boosting production, improving and preserving cerebral blood flow during reperfusion without necessitating peroxynitrite formation. Edaravone exerts its neuroprotective effect by mitigating neuronal damage from cerebral ischemia and inhibiting endothelial injury.
Cell Research	Cell viability is quantified by MTT assay and trypan blue staining. MTT (5?mg/mL, 20?μL) is added to each well and incubated for 4?h at 37°C after the drug treatments. The medium is removed and the cell pellet is dissolved in DMSO. Then, the optical density (OD) values are measured at 570?nm using an ELISA reader.
Synonyms	MCI-186

Chemical Properties

Molecular Weight	174.20
Formula	C₁₀H₁₀N₂O
Cas No.	89-25-8
Smiles	CC1=NN(C(=O)C1)C1=CC=CC=C1
Relative Density.	1.267 g/cm3. Temperature:20 °C.;1.266 g/cc. Temperature:20 °C.

Storage & Solubility Information

Storage

In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.

Solubility Information

DMSO: 247 mg/mL (1417.91 mM), Sonication is recommended.

In Vivo Formulation

5% DMSO+40% PEG300+5% Tween80+50% Saline: 4 mg/mL (22.96 mM), Sonication is recommended.

Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.

Solution Preparation Table

DMSO

	1mg	5mg	10mg	50mg
1 mM	5.7405 mL	28.7026 mL	57.4053 mL	287.0264 mL
5 mM	1.1481 mL	5.7405 mL	11.4811 mL	57.4053 mL
10 mM	0.5741 mL	2.8703 mL	5.7405 mL	28.7026 mL
20 mM	0.2870 mL	1.4351 mL	2.8703 mL	14.3513 mL
50 mM	0.1148 mL	0.5741 mL	1.1481 mL	5.7405 mL
100 mM	0.0574 mL	0.2870 mL	0.5741 mL	2.8703 mL

Calculator

Molarity Calculator
Dilution Calculator
Reconstitution Calculator
Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:

For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, TargetMol | Animal experiments

and a total of 10 animals are to be administered, using a formulation of TargetMol | reagent

10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH₂O , the resulting working solution concentration would be 2 mg/mL.

Stock Solution Preparation:

Dissolve 2 mg of the compound in 100 μL DMSO TargetMol | reagent to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.

Preparation of the In Vivo Formulation:

1) Add 100 μL of the DMSO TargetMol | reagent stock solution to 400 μL PEG300 and mix thoroughly until the solution becomes clear.

2) Add 50 μL Tween 80 and mix well until fully clarified.

3) Add 450 μL Saline,PBS or ddH₂O TargetMol | reagent and mix thoroughly until a homogeneous solution is obtained.

This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.

All co-solvents required for this protocol, includingDMSO, PEG300/PEG400, Tween 80, SBE-β-CD, and Corn oil, are available for purchase on the TargetMol website.

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc